Trials / Completed
CompletedNCT00490516
ACP-104 in Acutely Psychotic Subjects With Schizophrenia
A Six-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study of the Efficacy and Safety of ACP-104 in Acutely Psychotic Subjects With Schizophrenia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 247 (actual)
- Sponsor
- ACADIA Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, placebo-controlled parallel-group, 6-week study, evaluating two dose levels of ACP-104 or Placebo twice a day in patients with schizophrenia who are experiencing an acute psychotic episode.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACP-104 | 200 mg, tablet, BID, 6 weeks |
| DRUG | ACP-104 | 100 mg, tablet, BID, 6 weeks |
| DRUG | Placebo | placebo, tablet BID, 6 weeks |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2008-02-01
- Completion
- 2008-02-01
- First posted
- 2007-06-22
- Last updated
- 2025-01-20
Locations
21 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00490516. Inclusion in this directory is not an endorsement.